Your browser doesn't support javascript.
loading
CT Mucus Score and 129Xe MRI Ventilation Defects After 2.5 Years' Anti-IL-5Rα in Eosinophilic Asthma.
McIntosh, Marrissa J; Kooner, Harkiran K; Eddy, Rachel L; Wilson, Angela; Serajeddini, Hana; Bhalla, Anurag; Licskai, Christopher; Mackenzie, Constance A; Yamashita, Cory; Parraga, Grace.
Afiliação
  • McIntosh MJ; Robarts Research Institute; Department of Medical Biophysics, Western University, London, ON, Canada.
  • Kooner HK; Robarts Research Institute; Department of Medical Biophysics, Western University, London, ON, Canada.
  • Eddy RL; University of British Columbia Centre for Heart Lung Innovation, St. Paul's Hospital Vancouver, Vancouver, BC, Canada.
  • Wilson A; Robarts Research Institute.
  • Serajeddini H; Robarts Research Institute; Division of Respirology.
  • Bhalla A; Division of Respirology.
  • Licskai C; Division of Respirology.
  • Mackenzie CA; Division of Respirology; Division of Clinical Pharmacology and Toxicology, Department of Medicine, Western University, London, ON, Canada.
  • Yamashita C; Division of Respirology.
  • Parraga G; Robarts Research Institute; Department of Medical Biophysics, Western University, London, ON, Canada; Division of Respirology. Electronic address: gparraga@uwo.ca.
Chest ; 164(1): 27-38, 2023 07.
Article em En | MEDLINE | ID: mdl-36781102
BACKGROUND: We previously showed in patients with poorly controlled eosinophilic asthma that a single dose of benralizumab resulted in significantly improved Asthma Control Questionnaire (ACQ-6) score and 129Xe MRI ventilation defect percent (VDP) 28 days postinjection, and 129Xe MRI VDP and CT airway mucus occlusions were shown to independently predict this early ACQ-6 response to benralizumab. RESEARCH QUESTION: Do early VDP responses at 28 days persist, and do FEV1, fractional exhaled nitric oxide, and mucus plug score improve during a 2.5 year treatment period? STUDY DESIGN AND METHODS: Participants with poorly controlled eosinophilic asthma completed spirometry, ACQ-6, and MRI, 28 days, 1 year, and 2.5 years after initiation of treatment with benralizumab; chest CT was acquired at enrollment and 2.5 years later. RESULTS: Of 29 participants evaluated at 28 days post-benralizumab, 16 participants returned for follow-up while on therapy at 1 year, and 13 participants were evaluable while on therapy at 2.5 years post-benralizumab initiation. As compared with 28 days post-benralizumab, ACQ-6 score (2.0 ± 1.4) significantly improved after 1 year (0.5 ± 0.6, P = .02; 95% CI, 0.1-1.1) and 2.5 years (0.5 ± 0.5, P = .03; 95% CI, 0.1-1.1). The mean VDP change at 2.5 years (-4% ± 3%) was greater than the minimal clinically important difference, but not significantly different from VDP measured 28 days post-benralizumab. Mucus score (3 ± 4) was significantly improved at 2.5 years (1 ± 1, P = .03; 95% CI, 0.3-5.5). In six of eight participants with previous occlusions, mucus plugs vanished or substantially diminished 2.5 years later. VDP (P < .001) and mucus score (P < .001) measured at baseline, but not fractional exhaled nitric oxide or FEV1, independently predicted ACQ-6 score after 2.5 years. INTERPRETATION: In poorly controlled eosinophilic asthma, early MRI VDP responses at 28 days post-benralizumab persisted 2.5 years later, alongside significantly improved mucus scores and asthma control.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Eosinofilia Pulmonar / Asma / Antiasmáticos / Obstrução das Vias Respiratórias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Chest Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Eosinofilia Pulmonar / Asma / Antiasmáticos / Obstrução das Vias Respiratórias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Chest Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá